Adjuvant chemotherapy after pulmonary resection for lung cancer.
Fiche publication
Date publication
août 2013
Journal
Thoracic surgery clinics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Mascaux C, Shepherd FA
Lien Pubmed
Résumé
Adjuvant chemotherapy using a cisplatin-based regimen is currently recommended for patients with stage II and III non-small cell lung cancer (NSCLC) after complete tumor resection and may be considered for patients with stage IB NSCLC. Although adjuvant chemotherapy after complete resection of localized NSCLC is associated with an absolute survival advantage of approximately 5% at 5 years, there is still a relatively high risk of relapse even for early-stage NSCLC. Efforts are ongoing to identify new treatments in the adjuvant setting and to select patients for individualized treatment based on biomarkers.
Mots clés
Adjuvant, Biomarkers, Chemotherapy, Non–small cell lung cancer, Targeted therapy
Référence
Thorac Surg Clin. 2013 Aug;23(3):401-10